Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma

Breneman, Debra; Duvic, Madeleine; Kuzel, Timothy M.; Yocum, Richard C.; Truglia, J. A.; Stevens, Victor J.

doi:10.1001/archderm.138.3.325

Cited by 177 publications

(109 citation statements)

References 25 publications

(13 reference statements)

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…31,32,[41][42][43][44][45] Bexarotene is a new synthetic rexinoid that selectively binds to the RXR subfamily and is formulated as either as capsule or a topically applied gel. 46,47 In our experience, oral bexarotene can achieve responses in chemoradiotherapy refractory patients within 2 to 4 months, and those patients may have a sustained benefit provided that the RXR-induced hyperlipidemia is manageable, allowing an optimal therapeutic dose. Bexarotene may also be useful in maintaining responses after SDT.…”

Section: Retinoids and Rexinoidsmentioning

confidence: 97%

How I treat mycosis fungoides and Sézary syndrome

Prince

Whittaker

Hoppe

2009

Blood

136

109

View full text Add to dashboard Cite

The most common subtypes of primary cutaneous T-cell lymphomas are mycosis fungoides (MF) and Sézary syndrome (SS). The majority of patients have indolent disease; and given the incurable nature of MF/SS, management should focus on improving symptoms and cosmesis while limiting toxicity. Management of MF/SS should use a “stage-based” approach; treatment of early-stage disease (IA-IIA) typically involves skin directed therapies that include topical corticosteroids, phototherapy (psoralen plus ultraviolet A radiation or ultraviolet B radiation), topical chemotherapy, topical or systemic bexarotene, and radiotherapy. Systemic approaches are used for recalcitrant early-stage disease, advanced-stage disease (IIB-IV), and transformed disease and include retinoids, such as bexarotene, interferon-α, histone deacetylase inhibitors, the fusion toxin denileukin diftitox, systemic chemotherapy including transplantation, and extracorporeal photopheresis. Examples of drugs under active investigation include new histone deacetylase inhibitors, forodesine, monoclonal antibodies, proteasome inhibitors, and immunomodulatory agents, such as lenalidomide. It is appropriate to consider patients for novel agents within clinical trials if they have failed front-line therapy and before chemotherapy is used.

show abstract

Section: Retinoids and Rexinoidsmentioning

confidence: 97%

How I treat mycosis fungoides and Sézary syndrome

Prince

Whittaker

Hoppe

2009

Blood

136

109

View full text Add to dashboard Cite

show abstract

“…In a phase I/II study, 42 of 67 patients with stage IA-IIA disease achieved at least a partial response (PR; P50% improvement), and 21% of patients achieved a complete response (CR) based on the Physician's Global Assessment of skin involvement relative to baseline. 37 Efficacy improved with increases in concentration and frequency of application. 37 Bexarotene gel is generally well tolerated, with side-effects restricted to the site of application.…”

Section: Bexarotene Gelmentioning

confidence: 98%

“…37 Efficacy improved with increases in concentration and frequency of application. 37 Bexarotene gel is generally well tolerated, with side-effects restricted to the site of application. Bexarotene gel was approved by the FDA in June 2000 as therapy for stage IA-IIA CTCL.…”

Section: Bexarotene Gelmentioning

confidence: 98%

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Trautinger

Knobler

Willemze

et al. 2006

European Journal of Cancer

390

308

View full text Add to dashboard Cite

“…The most common toxicities are benign cutaneous reactions, including erythema, telangiectasias and hyperpigmentation. Bexarotene 1% gel is generally well tolerated and has been associated with an overall response rate of 63% (and complete response rate of 23%), prompting FDA approval for limited-stage CTCL in 2000 [211].…”

Section: Treatment Of Limited-stage Mfmentioning

confidence: 99%

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Wilcox

2011

American J Hematol

View full text Add to dashboard Cite

Disease overview: Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis fungoides (MF) or Sézary syndrome (SS).Diagnosis: The diagnosis of MF or SS requires the integration of clinical and histopathologic data.Risk‐adapted therapy: Tumor, node, metastasis, and blood (TNMB) staging remains the most important prognostic factor in MF/SS and forms the basis for a “risk‐adapted,” multidisciplinary approach to treatment. For patients with disease limited to the skin, expectant management or skin‐directed therapies is preferred, as both disease‐specific and overall survival for these patients is favorable. In contrast, patients with advanced‐stage disease with significant nodal, visceral, or blood involvement are generally approached with biologic‐response modifiers, denileukin diftitox, and histone deacetylase inhibitors before escalating therapy to include systemic, single‐agent chemotherapy. Multiagent chemotherapy may be used for those patients with extensive visceral involvement requiring rapid disease control. In highly‐selected patients with disease refractory to standard treatments, allogeneic stem‐cell transplantation may be considered. Am. J. Hematol., 2011. © 2011 Wiley‐Liss, Inc.

show abstract

Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma

Cited by 177 publications

References 25 publications

How I treat mycosis fungoides and Sézary syndrome

How I treat mycosis fungoides and Sézary syndrome

EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome

Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About